How blood-based diagnostics will save millions from cancer and billions in costs, with Oghuzan Atay.

Поделиться
HTML-код
  • Опубликовано: 17 окт 2024
  • BillionToOne founder & CEO Oghuzan Atay speaks to HOF investors Victor Wang and Sabrina Halper about the quantifiable impact of liquid biopsy on cancer outcomes and costs. He is building cutting-edge diagnostic technology to test DNA through blood samples instead of tissues and track cancer through blood rather than scans.

Комментарии •